• Results for the Second Quarter and First Half 2021

    Total revenues for the quarter ended at MNOK 109.8 (MNOK 82.5) and includes MNOK 5.3 granted by the U.S. Paycheck Protection Program related to COVID-19. Total revenues for the first half ended at MNOK 212.4…

    Read more
  • Results for the First Quarter 2021

    Sales for the quarter ended at MNOK 102.6 (MNOK 103.1), on par with the sales record set in Q1 last year. Currency neutral, sales increased by 1.5%. Second best quarter ever for operating result (EBIT)…

    Read more
  • Annual Report 2020

    Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second…

    Read more
  • Results for the Fourth Quarter and Preliminary Results for 2020

    Sales for the quarter ended at MNOK 94.2 (MNOK 95.7), a decrease of 1.6%. Sales for 2020 ended at MNOK 363.1 (MNOK 363.7). Operating result (EBIT) for the quarter ended at MNOK 22.1 (MNOK 19.7)…

    Read more
  • Results for the Third Quarter 2020

    Sales for the quarter ended at MNOK 83.4 (MNOK 85.5), a decrease of 2,5%. Read the full report and presentation below. Q3 report 2020 Q3 presentation 2020

    Read more
  • Results for the Second Quarter and First Half 2020

    Sales for the quarter ended at MNOK 82.5 (MNOK 93.8), a decrease of 12.2%. Sales for the 1st half ended at MNOK 185.6 (MNOK 182.5), a 1.7 % increase. Read the full report and presentation…

    Read more
  • Results for the First Quarter 2020

    Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

    Read more
  • Annual Report 2019

    We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

    Read more
  • Results for Fourth Quarter and Preliminary Results for Medistim for 2019

    Sales for the quarter ended at MNOK 95.7 (MNOK 97.9), while sales for 2019 ended at MNOK 363.7 (MNOK 325.9), a growth of 11.6%. Q4 2019 PresentationQ4 and preliminary year-end financials 2019

    Read more
  • Results for the Third Quarter 2019

    Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 %  growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…

    Read more